Two recent cases, New York v. Actavis PLC and In re: Suboxone Antitrust Litigation address monopolization claims related to “product hopping” – the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented. This program will bring together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.
WilmerHale Partner Mark Ford is a panelist at this event.
